Arginine glutamate versus ornithine aspartate for hepatic encephalopathy in cirrhosis

Phase 4, randomised, open-label trial of arginine glutamate and l-ornithine l-aspartate in hepatic encephalopathy (HE) and Cirrhosis (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: Improvement rate of hepatic encephalopathy after 7 days of treatment. Started May 2020; status: completed.